Additionally, hypomethylating agents, including AZA, have been shown to reduce the levels of MLC-1 in primary AML cells and induce a DNA damage response, leading to the upregulation of BH3-only proteins such as NOXA [45]. This evidence concerns the gene MLC1 and acute myeloid leukemia.